# Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice

> **NCT03895463** · — · WITHDRAWN · sponsor: **Ipsen**

## Conditions studied

- Neuroendocrine Tumors

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03895463
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-08
- **Primary completion:** 2023-03-26
- **Final completion:** 2023-03-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Reassessment of study feasibility
- **Last updated:** 2020-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03895463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03895463, "Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03895463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*